CP
CLRB icon

Caligan Partners’s Cellectar Biosciences CLRB Stock Holding History

Caligan Partners’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
+469,998
New +$1.31M 0.06% 28

Other funds holding CLRB

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Caligan Partners's CLRB Position: Q2 2026 in Review

Caligan Partners opened a new position in Cellectar Biosciences (CLRB) in Q2 2026: 469,998 shares worth $1.31M. The stake represents 0.06% of the portfolio and ranks #28 among its holdings.

27 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Caligan Partners held 469,998 shares of Cellectar Biosciences worth $1.31M as of Q2 2026.
  • Cellectar Biosciences was a new Caligan Partners position in Q2 2026.
  • Cellectar Biosciences made up 0.06% of Caligan Partners's portfolio in Q2 2026, its #28 holding.
  • 27 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.